Advertisement
News
Advertisement

Boston Scientific IONâ„¢ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data

Sun, 04/03/2011 - 7:33am
Bio-Medicine.Org

NATICK, Mass. and NEW ORLEANS, April 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION™ Platinum Chromium (PtCr) Paclitaxel-Eluting Stent System (TAXUS® Element™) compared to the currently available TAXUS® Liberte® Paclitaxel-Eluting Stent System.  Results were presented at the American College of Cardiology Annual Scientific Sessions by Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati and Principal Investigator for the PERSEUS clinical program.

"Although the ION and TAXUS Liberte Stents employ the same drug and polymer, the ION Stent demonstrated significantly lower rates of major adverse cardiac events (MACE), target lesion failure (TLF) and myocardial infarction (MI) in this case-matched analysis of nearly 2,300 patients," said Dr. Kereiakes.  "This study demonstrates that alloy composition, stent design and strut thickness may influence angiographic and clinical outcomes following drug-eluting stent deployment."

The study compared pooled patient-level data from 2,298 patients enrolled in the PERSEUS (ION Stent) and TAXUS ATLAS (TAXUS Liberte Stent) trials.  Propensity score matching was performed to adjust for differences in patient and lesion characteristics between the groups, and clinical follow-up was conducted out to 12 months.  Propensity-matched results in 1,326 patients revealed that the ION Stent achieved significantly lower rates of MACE (7.5 percent vs. 12.0 percent, p=0.007) and TLF (5.5 percent vs. 8.5 percent, p=0.04) largely driven by a reduction in myocardial infarction (1.8 percent vs. 3.9 percent, p=0.

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading